Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MYGN's Cash to Debt is ranked higher than
97% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. MYGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MYGN' s 10-Year Cash to Debt Range
Min: 16.5  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.86
MYGN's Equity to Asset is ranked higher than
88% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. MYGN: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
MYGN' s 10-Year Equity to Asset Range
Min: 0.73  Med: 0.89 Max: 0.94
Current: 0.86
0.73
0.94
Interest Coverage No Debt
MYGN's Interest Coverage is ranked higher than
94% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. MYGN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MYGN' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 6
Z-Score: 16.13
M-Score: -2.77
WACC vs ROIC
1.43%
14.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 18.56
MYGN's Operating margin (%) is ranked higher than
90% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. MYGN: 18.56 )
Ranked among companies with meaningful Operating margin (%) only.
MYGN' s 10-Year Operating margin (%) Range
Min: -134.85  Med: -32.16 Max: 39.24
Current: 18.56
-134.85
39.24
Net-margin (%) 11.09
MYGN's Net-margin (%) is ranked higher than
84% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. MYGN: 11.09 )
Ranked among companies with meaningful Net-margin (%) only.
MYGN' s 10-Year Net-margin (%) Range
Min: -89.39  Med: -23.95 Max: 42
Current: 11.09
-89.39
42
ROE (%) 11.60
MYGN's ROE (%) is ranked higher than
75% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. MYGN: 11.60 )
Ranked among companies with meaningful ROE (%) only.
MYGN' s 10-Year ROE (%) Range
Min: -25.88  Med: -10.42 Max: 30.71
Current: 11.6
-25.88
30.71
ROA (%) 10.13
MYGN's ROA (%) is ranked higher than
84% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.05 vs. MYGN: 10.13 )
Ranked among companies with meaningful ROA (%) only.
MYGN' s 10-Year ROA (%) Range
Min: -23.02  Med: -8.49 Max: 28.73
Current: 10.13
-23.02
28.73
ROC (Joel Greenblatt) (%) 100.11
MYGN's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. MYGN: 100.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -238.09  Med: -70.62 Max: 362.64
Current: 100.11
-238.09
362.64
Revenue Growth (3Y)(%) 19.20
MYGN's Revenue Growth (3Y)(%) is ranked higher than
88% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. MYGN: 19.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.7  Med: 21.30 Max: 44.9
Current: 19.2
1.7
44.9
EBITDA Growth (3Y)(%) -0.80
MYGN's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. MYGN: -0.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.6  Med: 12.15 Max: 47.2
Current: -0.8
-10.6
47.2
EPS Growth (3Y)(%) -6.00
MYGN's EPS Growth (3Y)(%) is ranked lower than
59% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. MYGN: -6.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -16.6  Med: 4.15 Max: 66.6
Current: -6
-16.6
66.6
» MYGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MYGN Guru Trades in Q3 2014

Jim Simons 60,474 sh (+22.91%)
Chase Coleman 1,900,000 sh (unchged)
First Pacific Advisors 251,100 sh (unchged)
John Burbank Sold Out
Andreas Halvorsen Sold Out
Richard Snow 1,055,014 sh (-3.32%)
Chuck Royce 8,906,065 sh (-4.23%)
Joel Greenblatt 869,531 sh (-22.18%)
Paul Tudor Jones 7,976 sh (-37.85%)
» More
Q4 2014

MYGN Guru Trades in Q4 2014

Ken Fisher 88,333 sh (New)
Steven Cohen 360,300 sh (New)
Jim Simons 94,000 sh (+55.44%)
Chase Coleman 1,900,000 sh (unchged)
First Pacific Advisors 251,100 sh (unchged)
Chuck Royce 5,900,143 sh (unchged)
Chuck Royce 5,900,143 sh (unchged)
Chuck Royce 5,084,563 sh (-13.82%)
Paul Tudor Jones 6,518 sh (-18.28%)
Richard Snow 827,803 sh (-21.54%)
Joel Greenblatt 568,865 sh (-34.58%)
Chuck Royce 5,084,563 sh (-42.91%)
» More
Q1 2015

MYGN Guru Trades in Q1 2015

Mario Gabelli 25,000 sh (New)
Louis Moore Bacon 20,795 sh (New)
Jim Simons 273,700 sh (+191.17%)
First Pacific Advisors 251,100 sh (unchged)
Richard Snow Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 88,050 sh (-0.32%)
Chuck Royce 3,404,200 sh (-33.05%)
Steven Cohen 153,400 sh (-57.42%)
Chase Coleman 291,097 sh (-84.68%)
» More
Q2 2015

MYGN Guru Trades in Q2 2015

Jim Simons 639,800 sh (+133.76%)
Mario Gabelli 25,000 sh (unchged)
Ken Fisher 88,050 sh (unchged)
Chase Coleman Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
First Pacific Advisors 233,200 sh (-7.13%)
Chuck Royce 2,823,203 sh (-17.07%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Myriad Genetics Inc

Chuck Royce Comments on Myriad Genetics - Oct 08, 2014

Six equity sectors made net contributions to first-half returns, with Health Care out in front, driven in large part by the terrific results for molecular diagnostic company Myriad Genetics (MYGN), which was among the portfolio’s five largest detractors in 2013 when we substantially increased our position. The company specializes in genetic testing for cancer and ended last year facing increased competition, particularly in breast cancer screening tests, and some still unresolved reimbursement issues that remained under federal review at the end of December. It was also facing skepticism from some quarters about the fallout from a June 2013 Supreme Court decision that genes could not be patented. Our take was that neither the high court ruling nor the increased competition would hurt the firm’s long-term health. We see the quality of its predictive tests as the industry’s gold standard, so we were quite pleased to see it continue to execute successfully (and profitably), as well as make a savvy acquisition of Crescendo Bioscience, in the first half. The acquisition diversifies Myriad’s already promising pipeline. It was the Fund’s largest holding at the end of June.

From Chuck Royce (Trades, Portfolio)’s Royce Premier Fund Second Quarter 2014 Manager Commentary.

Check out Chuck Royce latest stock trades

Top Ranked Articles about Myriad Genetics Inc

Chuck Royce Comments on Myriad Genetics
Six equity sectors made net contributions to first-half returns, with Health Care out in front, driven in large part by the terrific results for molecular diagnostic company Myriad Genetics (MYGN), which was among the portfolio’s five largest detractors in 2013 when we substantially increased our position. The company specializes in genetic testing for cancer and ended last year facing increased competition, particularly in breast cancer screening tests, and some still unresolved reimbursement issues that remained under federal review at the end of December. It was also facing skepticism from some quarters about the fallout from a June 2013 Supreme Court decision that genes could not be patented. Our take was that neither the high court ruling nor the increased competition would hurt the firm’s long-term health. We see the quality of its predictive tests as the industry’s gold standard, so we were quite pleased to see it continue to execute successfully (and profitably), as well as make a savvy acquisition of Crescendo Bioscience, in the first half. The acquisition diversifies Myriad’s already promising pipeline. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 33.80
MYGN's P/E(ttm) is ranked lower than
54% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. MYGN: 33.80 )
Ranked among companies with meaningful P/E(ttm) only.
MYGN' s 10-Year P/E(ttm) Range
Min: 9.09  Med: 19.03 Max: 80.49
Current: 33.8
9.09
80.49
Forward P/E 19.96
MYGN's Forward P/E is ranked higher than
53% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. MYGN: 19.96 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.70
MYGN's PE(NRI) is ranked lower than
54% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. MYGN: 33.70 )
Ranked among companies with meaningful PE(NRI) only.
MYGN' s 10-Year PE(NRI) Range
Min: 9.1  Med: 18.36 Max: 81.3
Current: 33.7
9.1
81.3
P/B 3.79
MYGN's P/B is ranked lower than
57% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. MYGN: 3.79 )
Ranked among companies with meaningful P/B only.
MYGN' s 10-Year P/B Range
Min: 2.32  Med: 3.74 Max: 8.23
Current: 3.79
2.32
8.23
P/S 3.75
MYGN's P/S is ranked lower than
57% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. MYGN: 3.75 )
Ranked among companies with meaningful P/S only.
MYGN' s 10-Year P/S Range
Min: 2.32  Med: 6.15 Max: 14.79
Current: 3.75
2.32
14.79
PFCF 23.06
MYGN's PFCF is ranked higher than
63% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. MYGN: 23.06 )
Ranked among companies with meaningful PFCF only.
MYGN' s 10-Year PFCF Range
Min: 7.63  Med: 16.64 Max: 140.77
Current: 23.06
7.63
140.77
POCF 19.28
MYGN's POCF is ranked higher than
57% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. MYGN: 19.28 )
Ranked among companies with meaningful POCF only.
MYGN' s 10-Year POCF Range
Min: 7.21  Med: 15.65 Max: 43.85
Current: 19.28
7.21
43.85
EV-to-EBIT 17.49
MYGN's EV-to-EBIT is ranked higher than
65% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. MYGN: 17.49 )
Ranked among companies with meaningful EV-to-EBIT only.
MYGN' s 10-Year EV-to-EBIT Range
Min: -102.6  Med: 9.05 Max: 52.4
Current: 17.49
-102.6
52.4
PEG 2.50
MYGN's PEG is ranked higher than
56% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. MYGN: 2.50 )
Ranked among companies with meaningful PEG only.
MYGN' s 10-Year PEG Range
Min: 0.43  Med: 0.76 Max: 2.3
Current: 2.5
0.43
2.3
Shiller P/E 23.15
MYGN's Shiller P/E is ranked higher than
64% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. MYGN: 23.15 )
Ranked among companies with meaningful Shiller P/E only.
MYGN' s 10-Year Shiller P/E Range
Min: 14.52  Med: 28.30 Max: 502.6
Current: 23.15
14.52
502.6
Current Ratio 4.13
MYGN's Current Ratio is ranked higher than
71% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. MYGN: 4.13 )
Ranked among companies with meaningful Current Ratio only.
MYGN' s 10-Year Current Ratio Range
Min: 2.58  Med: 5.47 Max: 17.26
Current: 4.13
2.58
17.26
Quick Ratio 3.76
MYGN's Quick Ratio is ranked higher than
70% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. MYGN: 3.76 )
Ranked among companies with meaningful Quick Ratio only.
MYGN' s 10-Year Quick Ratio Range
Min: 2.58  Med: 5.47 Max: 17.26
Current: 3.76
2.58
17.26
Days Inventory 61.07
MYGN's Days Inventory is ranked higher than
56% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. MYGN: 61.07 )
Ranked among companies with meaningful Days Inventory only.
MYGN' s 10-Year Days Inventory Range
Min: 22.14  Med: 48.31 Max: 60.67
Current: 61.07
22.14
60.67
Days Sales Outstanding 43.31
MYGN's Days Sales Outstanding is ranked higher than
78% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. MYGN: 43.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYGN' s 10-Year Days Sales Outstanding Range
Min: 9.44  Med: 48.11 Max: 90.17
Current: 43.31
9.44
90.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 61.75
MYGN's Price/Net Cash is ranked lower than
97% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. MYGN: 61.75 )
Ranked among companies with meaningful Price/Net Cash only.
MYGN' s 10-Year Price/Net Cash Range
Min: 3.83  Med: 9.54 Max: 57.61
Current: 61.75
3.83
57.61
Price/Net Current Asset Value 13.95
MYGN's Price/Net Current Asset Value is ranked lower than
70% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.66 vs. MYGN: 13.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MYGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.22  Med: 6.07 Max: 26.95
Current: 13.95
3.22
26.95
Price/Tangible Book 8.59
MYGN's Price/Tangible Book is ranked lower than
73% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. MYGN: 8.59 )
Ranked among companies with meaningful Price/Tangible Book only.
MYGN' s 10-Year Price/Tangible Book Range
Min: 1.68  Med: 3.60 Max: 19.83
Current: 8.59
1.68
19.83
Price/Projected FCF 1.00
MYGN's Price/Projected FCF is ranked higher than
85% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. MYGN: 1.00 )
Ranked among companies with meaningful Price/Projected FCF only.
MYGN' s 10-Year Price/Projected FCF Range
Min: 0.93  Med: 1.50 Max: 22.85
Current: 1
0.93
22.85
Price/Median PS Value 0.61
MYGN's Price/Median PS Value is ranked higher than
80% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. MYGN: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
MYGN' s 10-Year Price/Median PS Value Range
Min: 0.51  Med: 1.02 Max: 6.81
Current: 0.61
0.51
6.81
Price/Peter Lynch Fair Value 2.30
MYGN's Price/Peter Lynch Fair Value is ranked lower than
58% of the 26 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.96 vs. MYGN: 2.30 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.69  Med: 1.57 Max: 2.15
Current: 2.3
0.69
2.15
Price/Graham Number 3.45
MYGN's Price/Graham Number is ranked lower than
59% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. MYGN: 3.45 )
Ranked among companies with meaningful Price/Graham Number only.
MYGN' s 10-Year Price/Graham Number Range
Min: 1.02  Med: 2.08 Max: 3.22
Current: 3.45
1.02
3.22
Earnings Yield (Greenblatt) (%) 5.70
MYGN's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. MYGN: 5.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYGN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.9  Med: 9.35 Max: 22.7
Current: 5.7
1.9
22.7
Forward Rate of Return (Yacktman) (%) 19.41
MYGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
77% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. MYGN: 19.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYGN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -19.9  Med: 3.80 Max: 33.1
Current: 19.41
-19.9
33.1

Analyst Estimate

Jun16 Jun17 Jun18
Revenue(Mil) 776 800 817
EPS($) 1.82 1.98 2.12
EPS without NRI($) 1.82 1.98 2.12

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:MYD.Germany,
Myriad Genetics Inc is a molecular diagnostic company, engaged in making a difference in patients lives through the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. The Companys business segments include: research, molecular diagnostics and companion diagnostics. The research segment is engaged in the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to ensure optimal treatment, or assess a patients risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The Company markets these tests through its sales force of approximately 400 people in the United States. It also markets BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its European sales force. The Companys competitors include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The Company has 234 patents as well as patent applications in the United States and foreign countries. The patents and patent applications cover diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The Companys U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. The services that the Company provides are regulated by federal, state and foreign governmental authorities.
» More Articles for MYGN

Headlines

Articles On GuruFocus.com
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 
Myriad Genetics Inc. (MYGN) CFO James S Evans sells 8,400 Shares Mar 12 2010 

More From Other Websites
MYRIAD GENETICS INC Financials Aug 25 2015
Myriad Genetics upgraded by Wells Fargo Aug 25 2015
Myriad Genetics: myRisk Offers Strength, Currency Woes Linger Aug 18 2015
10-K for Myriad Genetics, Inc. Aug 14 2015
Myriad: Medicare Coverage for Prolaris Prostrate Cancer Test Aug 14 2015
Myriad Genetics (MYGN) Jumps: Stock Moves 6.8% Higher Aug 13 2015
Myriad Receives Favorable Medicare Final Coverage Decision for the Prolaris(R) Test Aug 13 2015
Myriad Receives Favorable Medicare Final Coverage Decision for the Prolaris(R) Test Aug 13 2015
MYRIAD GENETICS INC Files SEC form 10-K, Annual Report Aug 12 2015
Myriad Genetics Posts In-Line Earnings in Q4, Margins Suffer Aug 12 2015
Edited Transcript of MYGN earnings conference call or presentation 11-Aug-15 8:30pm GMT Aug 12 2015
Myriad meets 4Q profit forecasts Aug 11 2015
Myriad meets 4Q profit forecasts Aug 11 2015
Myriad Genetics Reports Fiscal Fourth-Quarter and Full Year 2015 Financial Results Aug 11 2015
Myriad Genetics Inc Earnings Call scheduled for 4:30 pm ET today Aug 11 2015
MYRIAD GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 11 2015
Myriad Genetics Reports Fiscal Fourth-Quarter and Full Year 2015 Financial Results Aug 11 2015
Q4 2015 Myriad Genetics Inc Earnings Release - After Market Close Aug 11 2015
Fossil Group, Myriad Genetics Among The Earnings Reports To Keep An Eye On Tuesday Aug 10 2015
PDF 12.06 KB Aug 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK